News

A trio of former and current neurology department directors discussed ways in which residency and fellowship programs may change as technology and therapeutic capabilities continue to expand. [WATCH TIME: 8 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 1, 2023.

When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.

Parkinsonian syndromes, including multiple systems atrophy and progressive supranuclear palsy, have similar symptoms to Parkinson disease but are more distinct and each have corresponding therapies that are available for them.

The associate professor of neurological sciences at the University of Vermont in Burlington discussed the persistent issue of delayed and misdiagnoses among patients with multiple sclerosis, highlighting the need to improve accurate diagnosis. [WATCH TIME: 3 minutes]

Findings of a new novel genetic risk factor could inform future GBA1 clinical trials, improving patient stratification and the odds of designing trials that are more likely to produce meaningful and actionable answers.

A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]

Despite pamrevlumab being generally safe and well tolerated, the potential first-in-class connective tissue growth factor inhibitor antibody did not meet its primary endpoint in a phase 3 trial for ambulator Duchenne muscular dystrophy.

Russell Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the ongoing collaboration focused on exploring the role of misfolded synuclein traditionally associated with Parkinson disease and in various forms of dementia.

Social determinants of health are conditions that people are born into and live under that affect their health, and can greatly impact clinical outcomes as well as contribute to health disparities and inequalities.

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, talked about the promising potential of BTK inhibitors in treating both relapsing and progressive forms of multiple sclerosis. [WATCH TIME: 6 minutes]

Findings from a real-world study among 120 patients with SMA suggests that nusinersen administration is safe and well tolerated, with only 30% of the patients mostly experiencing mild adverse events.

Despite the challenge of distinguishing tics from extra movements, machine learning technology could potentially help researchers with reducing time spent analyzing video recordings of patients with tic disorders.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

The chief medical officer at Avidity Biosciences discussed the phase 1/2 EXPLORE44 trial, assessing an investigational treatment for Duchenne muscular dystrophy, and highlighted the potential of the treatment based on the recent FDA orphan drug and fast track designations. [WATCH TIME: 4 minutes]

Swallowing difficulties, a major concern for patients with Parkinson disease, occurred rarely in the study, and were spontaneously resolved over time.

Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.

The associate staff member in the department of neurology at Cleveland Clinic discussed the major take-home points and post-hoc findings from a positive study of deep brain stimulation in poststroke patients. [WATCH TIME: 3 minutes]

The distinguished investigator at the National Institutes of Health provided insight on the topic of globalizing Parkinson disease genetics, and how it may lead to potential disease-modifying therapies.

The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.

Christy Sheehy, PhD, chief executive officer and cofounder of C. Light Technologies, talked about the FDA clearance of Retitrack—retinal eye-movement monitor—and how the device holds promise for facilitating more accurate ocular motor assessments at bedside.

Previous neuroimaging studies in Parkinson disease suggest an altered interaction at a structural and functional level between cortical and subcortical areas of the brain that each contribute to gait dysfunction.

Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.

The professor of neurology at Washington University School of Medicine discussed the growing sense of hope among patients with progressive multiple sclerosis as providers gain an understanding in treating this form of the disease. [WATCH TIME: 3 minutes]

Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

After a year of treatment, patients showed significant improvements in ON time without troublesome dyskinesia, with more apparent effects observed in the high-dose group.

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

As part of our monthly clinician spotlight, NeurologyLive® highlighted expert Gary Hisch, MD, pediatric neurologist at Cleveland Clinic, who oversees programs for neuromuscular disorders such as for patients with spinal muscular atrophy.

The neurosurgeon at Allegheny Health Network discussed the current uses of GammaTile following tumor removal, and the research needed to unlock greater potential. [WATCH TIME: 3 minutes]